962
Views
16
CrossRef citations to date
0
Altmetric
Review

Emerging therapeutic targets for Gaucher disease

, , &

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Jenny Kim, Ellen Sidransky & Grisel Lopez. (2015) Understanding and managing parkinsonism in patients with glucocerebrosidase mutations. Expert Opinion on Orphan Drugs 3:5, pages 549-562.
Read now

Articles from other publishers (15)

Manoj Kumar Pandey. (2023) Exploring Pro-Inflammatory Immunological Mediators: Unraveling the Mechanisms of Neuroinflammation in Lysosomal Storage Diseases. Biomedicines 11:4, pages 1067.
Crossref
Batoul M. Issleny, Rama Jamjoum, Saurav Majumder & Johnny Stiban. 2023. History of The Enzymes, Current Topics and Future Perspectives. History of The Enzymes, Current Topics and Future Perspectives 171 201 .
Chandra Sekhar Boddupalli, Shiny Nair, Glenn Belinsky, Joseph Gans, Erin Teeple, Tri-Hung Nguyen, Sameet Mehta, Lilu Guo, Martin L Kramer, Jiapeng Ruan, Honggge Wang, Matthew Davison, Dinesh Kumar, DJ Vidyadhara, Bailin Zhang, Katherine Klinger & Pramod K Mistry. (2022) Neuroinflammation in neuronopathic Gaucher disease: Role of microglia and NK cells, biomarkers, and response to substrate reduction therapy. eLife 11.
Crossref
Laetitia Francelle & Joseph R. Mazzulli. (2022) Neuroinflammation in Gaucher disease, neuronal ceroid lipofuscinosis, and commonalities with Parkinson’s disease. Brain Research 1780, pages 147798.
Crossref
Daria Messelodi, Salvatore Nicola Bertuccio, Valentina Indio, Silvia Strocchi, Alberto Taddia, Salvatore Serravalle, Jessica Bandini, Annalisa Astolfi & Andrea Pession. (2021) iPSC-Derived Gaucher Macrophages Display Growth Impairment and Activation of Inflammation-Related Cell Death. Cells 10:11, pages 2822.
Crossref
Azucena Perez-Canamas, Hideyuki Takahashi, Jane A Lindborg & Stephen M Strittmatter. (2021) Fronto-temporal dementia risk gene TMEM106B has opposing effects in different lysosomal storage disorders . Brain Communications 3:1.
Crossref
Ayelet Vardi, Shifra Ben-Dor, Soo Min Cho, Ulrich Kalinke, Julia Spanier & Anthony H. Futerman. (2020) Mice defective in interferon signaling help distinguish between primary and secondary pathological pathways in a mouse model of neuronal forms of Gaucher disease. Journal of Neuroinflammation 17:1.
Crossref
Giulia Massaro, Michael P Hughes, Sammie M Whaler, Kerri-Lee Wallom, David A Priestman, Frances M Platt, Simon N Waddington & Ahad A Rahim. (2020) Systemic AAV9 gene therapy using the synapsin I promoter rescues a mouse model of neuronopathic Gaucher disease but with limited cross-correction potential to astrocytes. Human Molecular Genetics 29:12, pages 1933-1949.
Crossref
Ana R. P. Varela, Ana E. Ventura, Ana C. Carreira, Aleksander Fedorov, Anthony H. Futerman, Manuel Prieto & Liana C. Silva. (2017) Pathological levels of glucosylceramide change the biophysical properties of artificial and cell membranes. Physical Chemistry Chemical Physics 19:1, pages 340-346.
Crossref
Ayelet Vardi, Hila Zigdon, Anna Meshcheriakova, Andrés D Klein, Chen Yaacobi, Raya Eilam, Brandon M Kenwood, Ahad A Rahim, Giulia Massaro, Alfred H MerrillJrJr, Einat B Vitner & Anthony H Futerman. (2016) Delineating pathological pathways in a chemically induced mouse model of Gaucher disease. The Journal of Pathology 239:4, pages 496-509.
Crossref
John Marshall, Ying Sun, Dinesh S Bangari, Eva Budman, Hyejung Park, Jennifer B Nietupski, Amy Allaire, Mary A Cromwell, Bing Wang, Gregory A Grabowski, John P Leonard & Seng H Cheng. (2016) CNS-accessible Inhibitor of Glucosylceramide Synthase for Substrate Reduction Therapy of Neuronopathic Gaucher Disease. Molecular Therapy 24:6, pages 1019-1029.
Crossref
Melinda Barkhuizen, David G. Anderson & Anne F. Grobler. (2016) Advances in GBA-associated Parkinson's disease – Pathology, presentation and therapies. Neurochemistry International 93, pages 6-25.
Crossref
Elena M. Sánchez-Fernández, José M. García Fernández & Carmen Ortiz Mellet. (2016) Glycomimetic-based pharmacological chaperones for lysosomal storage disorders: lessons from Gaucher, G M1 -gangliosidosis and Fabry diseases . Chemical Communications 52:32, pages 5497-5515.
Crossref
Arnold E. Stütz & Tanja M. Wrodnigg. 2016. 225 302 .
Marie T. Vanier, Catherine Caillaud & Thierry Levade. 2016. Inborn Metabolic Diseases. Inborn Metabolic Diseases 551 575 .

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.